PMID- 33123131
OWN - NLM
STAT- MEDLINE
DCOM- 20210430
LR  - 20210430
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 11
DP  - 2020
TI  - Tolerogenic Dendritic Cells: The Pearl of Immunotherapy in Organ Transplantation.
PG  - 552988
LID - 10.3389/fimmu.2020.552988 [doi]
LID - 552988
AB  - Over a half century, organ transplantation has become an effective method for the 
      treatment of end-stage visceral diseases. Although the application of 
      immunosuppressants (IS) minimizes the rate of allograft rejection, the common use 
      of IS bring many adverse effects to transplant patients. Moreover, true 
      transplant tolerance is very rare in clinical practice. Dendritic cells (DCs) are 
      thought to be the most potent antigen-presenting cells, which makes a bridge 
      between innate and adaptive immunity. Among their subsets, a small portion of DCs 
      with immunoregulatory function was known as tolerogenic DC (Tol-DC). Previous 
      reports demonstrated the ability of adoptively transferred Tol-DC to approach 
      transplant tolerance in animal models. In this study, we summarized the 
      properties, ex vivo generation, metabolism, and clinical attempts of Tol-DC. 
      Tol-DC is expected to become a substitute for IS to enable patients to achieve 
      immune tolerance in the future.
CI  - Copyright (c) 2020 Zhuang, Cai, Cao, Li, Liu and Ming.
FAU - Zhuang, Quan
AU  - Zhuang Q
AD  - Transplantation Center of the 3rd Xiangya Hospital, Central South University, 
      Changsha, China.
AD  - Research Center of National Health Ministry on Transplantation Medicine, 
      Changsha, China.
FAU - Cai, Haozheng
AU  - Cai H
AD  - Transplantation Center of the 3rd Xiangya Hospital, Central South University, 
      Changsha, China.
FAU - Cao, Qingtai
AU  - Cao Q
AD  - Hunan Normal University School of Medicine, Changsha, China.
FAU - Li, Zixin
AU  - Li Z
AD  - Hunan Normal University School of Medicine, Changsha, China.
FAU - Liu, Shu
AU  - Liu S
AD  - Transplantation Center of the 3rd Xiangya Hospital, Central South University, 
      Changsha, China.
AD  - Research Center of National Health Ministry on Transplantation Medicine, 
      Changsha, China.
FAU - Ming, Yingzi
AU  - Ming Y
AD  - Transplantation Center of the 3rd Xiangya Hospital, Central South University, 
      Changsha, China.
AD  - Research Center of National Health Ministry on Transplantation Medicine, 
      Changsha, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20201006
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
SB  - IM
MH  - Animals
MH  - *Dendritic Cells/immunology/transplantation
MH  - *Graft Rejection/immunology/prevention & control
MH  - Graft Survival/*immunology
MH  - Humans
MH  - *Immunotherapy
MH  - *Organ Transplantation
MH  - *Transplantation Tolerance
PMC - PMC7573100
OTO - NOTNLM
OT  - dendritic cell
OT  - immune tolerance
OT  - metabolism
OT  - organ transplantation
OT  - tolerogenic dendritic cell
EDAT- 2020/10/31 06:00
MHDA- 2021/05/01 06:00
PMCR- 2020/01/01
CRDT- 2020/10/30 05:53
PHST- 2020/04/17 00:00 [received]
PHST- 2020/08/12 00:00 [accepted]
PHST- 2020/10/30 05:53 [entrez]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2021/05/01 06:00 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2020.552988 [doi]
PST - epublish
SO  - Front Immunol. 2020 Oct 6;11:552988. doi: 10.3389/fimmu.2020.552988. eCollection 
      2020.